

Results of the
RESPOND-CRT
T R I A L



THE RESPOND CRT SYSTEM WITH SONR TECHNOLOGY IS NOT AVAILABLE FOR SALE OR DISTRIBUTION IN THE USA.
LIMITED BY FEDERAL (OR UNITED STATES) LAW TO INVESTIGATIONAL USE.

The Respond CRT System™

is a unique combination of a cardiac
contractility sensor with an advanced
optimization algorithm*.


*The Respond CRT™ system with SonR™ technology is not available for sale or distribution in the USA.

SonR™ TECHNOLOGY

A CARDIAC CONTRACTILITY SENSOR*



The SonR™ sensor consists of a micro-accelerometer embedded in the tip of the SonRtip™ atrial lead. SonR™ measures the vibrations generated by the myocardium during cardiac contractions, which are correlated to LV dP/dt max.^{1,2,3}



AV & VV OPTIMIZATION ALGORITHM

The SonR™ sensor continuously measures the contractility of the heart allowing for automatic optimization of AV and VV intervals. Optimization is performed on a weekly basis both at rest and during exercise.

This allows for cardiac resynchronization therapy to be continuously adapted to the individual needs of each patient.


About

THE RESPOND-CRT TRIAL

RESPOND-CRT is an international, multicenter, randomized (2:1), prospective, double-blinded, non-inferiority study. The objective was to demonstrate that automatic optimization with SonR™ technology was safe and as effective as best practice AV and VV optimization using echocardiography.

The RESPOND-CRT trial successfully met its primary end point with 75% of clinical responders in the SonR group versus 70% in the control group at 12 months.⁴ (p<0.001)

Clinical Response* to CRT



75%

of clinical responders⁴.

The highest rate of responders ever reported using automatic device-based optimization.^{5,6,7}


*RESPONDERS RATE DEFINED AS PATIENTS ALIVE AND FREE FROM HF EVENTS AT 12 MONTHS, WITH IMPROVED NYHA CLASS OR QUALITY OF LIFE

Risk reduction in HF hospitalization

35%

Long term follow up shows a significant risk reduction in HF hospitalization for patients optimized with the Respond CRT System™. ⁴

Freedom from HF hospitalization




N°. at risk	0	2	4	6	8	10	12	14	16	18	20	22	24
SonR	670	641	617	600	588	579	498	418	408	339	250	244	135
Echo	328	315	304	289	277	269	229	191	189	171	119	144	49

Consistently favorable response in most subgroups⁴

Clinical **response across the board** is more likely with the Respond CRT System™, whatever the patients' baseline conditions.⁴

Responder rate, odds ratio and interaction P value for subgroups*



*P values <0.15 were considered significant for interaction

CRT Response Rate Improvement

SONR VERSUS ECHO AV & VV




22%

absolute higher response in patients with AF history ⁴

16%

absolute higher response in patients with renal dysfunction ⁴



The SonR™ sensor

Continuously measures cardiac contractility
for automatic, individualized CRT optimization.

References

1. Rickards AF, Bombardini T, Corbucci G et al. An implantable intracardiac accelerometer for monitoring myocardial contractility. The multicenter PEA Study group. *Pacing Clin Electrophysiol* 1996;19:2066-2071.
2. Bongiorni MG, Soldati E, Arena G et al. Local myocardial contractility related to endocardial acceleration signals detected by a transvenous pacing lead. *Pacing Clin Electrophysiol* 1996;19:1682-1688.
3. Bordachar P, Garrigue S, Ritter P et al. Contributions of a hemodynamic sensor embedded in an atrial lead in a porcine model. *J Cardiovasc Electrophysiol*. 2011;22(5):579-83.
4. Brugada J, Delnoy P P, Brachmann J et al. Contractility sensor-guided optimization of cardiac resynchronization therapy: results from the RESPOND-CRT trial. *Eur. Heart J* 2016;0:1-9.
5. Ellenbogen KA, Gold MR, Meyer TE et al. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. *Circulation* 2010;122:2260-8.
6. Abraham WT, Gras d, Yu CM et al. Results from the freedom trial. Assess the safety and efficacy of frequent optimization of cardiac resynchronization therapy. *Heart Rhythm, Scientific Sessions* 2010.
7. Martin DO, Lemke B, Krum H et al. Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: results of the adaptive CRT trial. *Heart Rhythm* 2012;9:1807-14.